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ABSTRACT
Objective: The assessment of behavioral disturbances in amyotrophic lateral sclerosis (ALS) is impor-
tant because of the overlap with the behavioral variant of frontotemporal dementia (ALS-bvFTD).
Motor symptoms and dysarthria are not taken into account in currently used behavioral question-
naires. We examined the clinimetric properties of a new behavioral questionnaire for patients with
ALS (Amyotrophic Lateral Sclerosis-Frontotemporal Dementia-Questionnaire [ALS-FTD-Q]).
Methods: In addition to other clinimetric properties, we examined reliability, clinical validity, and
construct validity of the ALS-FTD-Q, using data from patients with ALS (n  103), ALS-bvFTD
(n 10), bvFTD (n 25), muscle disease control subjects (n 39), and control subjects (n 31).
Construct validity of the ALS-FTD-Q was assessed using the Frontal Systems Behavior scale
(FrSBe), Frontal Behavioral Inventory (FBI), Hospital Anxiety and Depression Scale, ALS Func-
tional Rating ScaleRevised, Frontal Assessment Battery, Mini-Mental State Examination, and a
fluency index. In addition, the point prevalence of behavioral disturbances according to the ALS-
FTD-Q was compared with those obtained with the FrSBe and FBI.
Results: The internal consistency of the ALS-FTD-Q was good (Cronbach   0.92). The ALS-
FTD-Q showed construct validity because it correlated highly with other behavioral measures (r
0.80 and 0.79), moderately with measures of frontal functions and global cognitive functioning
(r 0.37; r 0.32), and poorly with anxiety/depression andmotor impairment (r 0.18 for both).
The ALS-FTD-Q discriminated between patients with ALS-bvFTD, patients with ALS, and control
subjects. The point prevalence of behavioral disturbances in patients with ALSmeasured with the
ALS-FTD-Q was lower than that for the FrSBe and FBI.
Conclusion: The ALS-FTD-Q is a feasible and clinimetrically validated instrument for the screen-
ing of behavioral disturbances in ALS. Neurology® 2012;79:1377–1383
GLOSSARY
ALS  amyotrophic lateral sclerosis; ALSFRS-R  ALS Functional Rating ScaleRevised; ALS-FTD-Q  Amyotrophic Lat-
eral Sclerosis-Frontotemporal DementiaQuestionnaire; bvFTD  behavioral variant of frontotemporal dementia; FAB 
Frontal Assessment Battery; FBI Frontal Behavioral Inventory; FrSBe Frontal Systems Behavior scale;HADSHospital
Anxiety and Depression Scale; MMSEMini-Mental State Examination.
The frontotemporal brain regions are affected in a proportion of patients with amyotrophic
lateral sclerosis (ALS).1–3 Clinically, this may lead to the behavioral variant of frontotemporal
dementia (bvFTD) (in 5%–10% of patients with ALS), mild frontotemporal cognitive deficits
(in 32%–45% of patients with ALS), or mild behavioral disturbances in patients with ALS.4–8
These nonmotor changes in patients with ALS may negatively influence survival and hinder
adherence to therapeutic interventions and relations with caregivers.9–11
The gold standard for behavioral disturbances is a detailed family interview. When this is
not feasible, a neuropsychiatric screening instrument is an alternative. Importantly, the scoring
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of items should not be influenced by muscle
weakness, dysarthria, or pseudobulbar affect,
as these may overestimate behavioral distur-
bances in patients with ALS.12
The neuropsychiatric instruments currently
available for assessing behavior have not been
validated in patients with ALS and contain sev-
eral items that rely on the ability to speak, eat,
and move without problems.13–15 To overcome
these issues, we investigated the clinimetric
properties of a new screening tool, the Amyotro-
phic Lateral Sclerosis-FrontotemporalDementia
Questionnaire (ALS-FTD-Q), for the detection
of bvFTD and mild behavioral disturbances
in ALS.
METHODS Subjects. Five groups of patients were recruited
from tertiary referral centers for ALS and dementia, all in the
Netherlands: 103 patients with ALS (possible, probable, or defi-
nite ALS according to the El Escorial criteria)16; 10 patients with
ALS-bvFTD who had the diagnosis of ALS-bvFTD by the treat-
ing clinician before this study, according to the El Escorial16 and
Neary criteria17; 25 patients with bvFTD without ALS that had
been diagnosed before the study, according to the Neary crite-
ria17; 39 patients with muscle diseases (muscle controls) (inclu-
sion body myositis [n  10], limb girdle dystrophy 2A [n  8],
oculopharyngeal muscular dystrophy [n  6], Miyoshi myop-
athy [n  9], and ALS mimics [n  6]); and 31 subjects evalu-
ated at the outpatient neurology clinic for diverging symptoms
(e.g., sensory symptoms, tremor, and headache) (other controls).
These subjects had no medical history of muscle disease, CNS
disorder, or psychiatric disorder. The patients with ALS-bvFTD
and bvFTD served as positive controls (n  35); the patients
with muscle diseases and the other controls served as negative
controls (n 70).
Only patients with a proxy were included. A proxy can be a
partner, parent, sibling, adult child, or other caregiver who is
able to assess the patient’s behavior. In 1.6% of the patients
contacted, absence of a proxy was the reason not to participate.
Patients and control subjects were excluded if they did not speak
Dutch fluently or if they had a (history of a) psychiatric disorder
or a neurologic disease with CNS involvement.
Standard protocol approvals, registrations, and patient
consents. The local ethics committees of the participating hos-
pitals approved the study. Written informed consent was ob-
tained from all subjects.
ALS-FTD-Q. The ALS-FTD-Q (appendix e-1on theNeurology®
Web site at www.neurology.org and on www.alsftdq.nl) is an ob-
server report scale aimed at the proxy of a patient with ALS.
Items for the ALS-FTD-Q were taken from a systematic review
of neurobehavioral symptoms (i.e., behavioral, cognitive, and
psychiatric disturbances) in 170 published patients with motor
neuron disease and bvFTD,18 and the item selection was mainly
based on the pooled prevalence rates of neurobehavioral symp-
toms in the review. The phrasing of the items was adjusted for
motor and speech dysfunction. Face validity of the ALS-FTD-Q
is described in appendix e-2. The ALS-FTD-Q has 25 items
(including 3 cognitive items: memory, concentration, and orien-
tation in time), with a 4-point rating scale; the maximum score
of the ALS-FTD-Q is 100. A higher score indicates more behav-
ioral disturbances. The time required to complete the question-
naire was estimated to be between 5 and 10 minutes.
Procedure. Most patients with ALS were visited at home (n 
97, including 9 patients with ALS-bvFTD). The proxy was re-
quested to fill in the ALS-FTD-Q and 2 other behavioral scales
(for instruments, see below) in a separate room while the patient
underwent a short battery of tests that assessed cognitive and
affective functions and functional motor status. Proxies of 16
consecutive patients with ALS (including 1 patient with ALS-
bvFTD) filled in the ALS-FTD-Q during an outpatient clinic
visit, separate from the home-visit study.
Proxies of the other patients and control subjects filled in the
ALS-FTD-Q at the outpatient clinics during a regular visit, in a
room separated from the patient.
Instruments used in the home-visit study. The proxy
assessed the behavior of the patient with the ALS-FTD-Q and
the Frontal Systems Behavior Scale (FrSBe), a 46-item behavior
scale with carer ratings of premorbid and postmorbid behavior in
the domains of apathy, executive dysfunction, and disinhibi-
tion,14 and the Frontal Behavioral Inventory (FBI), a 24-item
scale measuring frontal lobemediated behavior.15
The patient was administered the Mini-Mental State Exam-
ination (MMSE)19; the Frontal Assessment Battery (FAB), a
6-item instrument measuring frontal lobe functions, e.g., con-
ceptualization and perseveration20; letter (D, A, T) and category
(animals and occupations) fluency, measures of executive func-
tion with correction for speech/motor dysfunction by calculating
a mean thinking time per word in seconds (fluency index)12,21
(written or spoken versions were used, depending on disability);
the Hospital Anxiety and Depression Scale (HADS), a 14-item
scale22; and the ALS Functional Rating ScaleRevised
(ALSFRS-R), a 12-item questionnaire for motor dysfunction in
ALS.23
Patients in whom impaired manual dexterity precluded per-
formance of the “writing a sentence” item of the MMSE were
allowed to say the sentence, provided their speech was intelligi-
ble. For other items that require manual dexterity, e.g., “inter-
secting pentagons” of the MMSE and 5 of the 6 items of the
FAB, a note was made when these tasks could not be performed.
We recorded the score obtained and the highest obtainable score.
The highest obtainable score is the score if all items are done
perfectly, leaving out the items missed due to motor impairment.
Extrapolated scores of the MMSE and FAB were used for
analyses, according to the formula: extrapolated score  score
obtained  maximum scale score/highest obtainable score
for this patient. A higher extrapolated score means a better
performance.
Disease onset was defined as the month when the first sign of
muscle weakness (ALS) or behavioral changes (bvFTD) was
noted. Bulbar involvement was defined as a score 11 on the 3
bulbar items of the ALSFRS-R.
Clinimetric evaluation of ALS-FTD-Q. The following
clinimetric properties of the ALS-FTD-Q were studied: reliabil-
ity (both internal consistency and test-retest reliability), con-
struct validity, clinical validity, and the presence of a floor and
ceiling effect.
Internal consistency refers to the statistical coherence of the
scale items and can be measured by the Cronbach  coefficient,
which is based on the weighted average correlation of items
within a scale. Internal consistency is considered to be good if
 0.80. We calculated item-total correlations, which represent
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the correlation of a single item with the sum of all other scale
items. Correlations0.30 were considered to be sufficient. Test-
retest reliability was investigated in a pilot study on the proxies of
17 patients with ALS, including 4 patients with ALS-bvFTD
(appendix e-2).
Construct validity was assessed in the group of 97 patients
with ALS (including 9 patients with ALS-bvFTD) who under-
went multiple tests at home. We measured the extent to which
the ALS-FTD-Q correlates with measures that address the same
concept (i.e., frontal behavior) and measures that address dif-
ferent concepts. We assumed that for the ALS-FTD-Q to be
valid, the ALS-FTD-Q scores had to show high correlations
with the other frontal behavior scale scores (FrSBe and FBI),
moderate correlations with frontal lobe functions (FAB and
fluency) and global cognitive functions (MMSE), and low
correlations with affective functions (HADS) and motor
functions (ALSFRS-R).
A scale demonstrates clinical validity if it discriminates be-
tween groups of patients with known differences in clinical sta-
tus (i.e., ALS without bvFTD vs bvFTD with or without ALS).
Floor and ceiling effects of the ALS-FTD-Q were analyzed (per-
centage of patients with a minimum and maximum score).
ALS-FTD-Q vs comparable scales. To explore whether the
results of the ALS-FTD-Q differ from scales that are currently
used in patients with ALS, we compared point prevalences of
abnormal behavior assessed with the ALS-FTD-Q (using tenta-
tive cutoff scores derived from our negative and positive control
groups) with those from the FrSBe and the FBI (using published
cutoff scores). We aimed to compare the ALS-FTD-Q scores
with scores for the other scales for both mildly and severely ab-
normal behavior, because a spectrum of behavioral disturbances
in ALS has been suggested in earlier studies.24,25 The cutoff of the
ALS-FTD-Q indicating mild disturbances (below which behav-
ior is normal) was based on the 95th percentile of the 70 negative
controls. The cutoff indicating severe disturbances (in the
bvFTD range) was based on the lowest ALS-FTD-Q score in the
group of 35 positive control subjects (patents with bvFTD and
ALS-bvFTD). For the comparison with other scales, for mild
disturbances we used the cutoff score of the FrSBe (t score 65;
1.5 SD above the mean),14 and for severe disturbances we used
the published cutoff score of the FBI.15 We assessed performance
on the ALS-FTD-Q in patients with incident and prevalent dis-
ease. Patients with incident disease were defined as being assessed
within 1 year from the diagnosis.9
Statistical analysis. Internal consistency of the ALS-FTD-Q
scores was expressed as Cronbach  coefficient. Item-total corre-
lations and test-retest correlations were expressed as Pearson cor-
relation coefficients (r) and intraclass correlation coefficients,
respectively. Associations between the ALS-FTD-Q scores and
the other measures were expressed as Spearman rank correlation
coefficients (rs). Differences between ALS-FTD-Q scores and
patient characteristics in relation to the various subgroups were
analyzed using the Mann-WhitneyU test, Kruskal-Wallis test, or
2 test. Statistical significance level was set at p 0.05. Analyses
were performed in PASW statistics, version 18 (SPSS).
RESULTS We included 113 patients with ALS (80
male [70.8%]), 10 of whom were diagnosed with
ALS-bvFTD before the study. The mean age at ex-
amination was 61.3 years (SD 11.7), and the median
disease duration was 2.8 years (34 months, range
4–328 months) (table 1). Ninety-three patients
(82.3%) had limb-onset ALS. Bulbar involvement
was present in 72 patients (63.7%). Gender and age
were not different among any of the groups.
Clinimetrics. The ALS-FTD-Q scores showed sub-
stantial internal consistency (Cronbach   0.92),
and 23 of the 25 items showed an item-total score
correlation ranging between 0.31 and 0.78. Two
items (hypersexuality and euphoria) had an item-
total score correlation of 0.20 and 0.26. The test-
retest intraclass correlation of the ALS-FTD-Q total
score was 0.89 (n 17; mean time between 2 assess-
ments 65 days [SD 26.7]) (additional data for the
test-retest group are given in appendix e-2).
Construct validity was shown by high correlations
between the ALS-FTD-Q and the FrSBe and FBI,
moderate correlations with the FAB, fluency, and
MMSE, and low correlations with the HADS and
Table 1 Demographic and clinical characteristics of the patients with ALS and positive and negative control
subjects assessed with the ALS-FTD-Q
ALS (n 103)
Positive control subjects Negative control subjects
ALS-bvFTD
(n 10)
bvFTD
(n 25)
Muscle disease
(n 39)
Other controls
(n 31)
Age, y, mean (SD) 61.4 (11.9) 60.2 (10.4) 63.4 (6.4) 58.7 (13.3) 58.3 (11.7)
Sex, M/F 73/30 7/3 17/8 22/17 15/16
Limb/bulbar onset, n 89/14 4/6
Bulbar involvement,%a 60.2 100 38.5
Disease duration, mo,
median (range)
33.5 (4328) 35.5 (080) 48 (13355) 153 (12519)
ALSFRS-Rb 31.5 (9.2) 32.9 (6.1)
Abbreviations: ALS  amyotrophic lateral sclerosis; ALSFRS-R  ALS Functional Rating ScaleRevised; ALS-FTD-Q 
Amyotrophic Lateral Sclerosis-Frontotemporal DementiaQuestionnaire; bvFTD  behavioral variant of frontotemporal
dementia.
a Bulbar involvement was defined as a score11 on the 3 bulbar items of the ALSFRS-R.
b The maximum score of the ALSFRS-R is 48 and indicates no motor dysfunction.
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ALSFRS-R (table 2, figure 1). There was a floor ef-
fect (16 of 208 patients [7.7%] had a minimum score
of 0); no ceiling effect was observed.
With regard to clinical validity, the median ALS-
FTD-Q score of patients with ALS without bvFTD
(9, range 0–46) was lower than those for either pa-
tients with ALS-bvFTD (42, range 30–56) or pa-
tients with bvFTD (50, range 29–68) and higher
than those for the muscle disease control group (6,
range 0–24) and the other control subjects (5, range
0–20) (figure 2).
ALS-FTD-Q and comparable scales. Based on our
scoring algorithm (Methods section), the ALS-
FTD-Q cutoff indicating mild disturbances was set
at 22; the cutoff indicating severe disturbances (in
the bvFTD range) was set at 29. In patients with-
out a prior diagnosis of bvFTD who had complete
data for the 3 behavioral scales (n  86), mild and
severe behavioral disturbances were shown in 11
(10.7%) and 7 patients (6.8%), respectively, with the
ALS-FTD-Q. In comparison, according to the FrSBe
and FBI, 16 patients (18.6%) had mild behavioral
disturbances and 12 patients (14%) had severe be-
havioral changes. Of the 103 patients who were as-
sessed with the ALS-FTD-Q, 27 (26.2%) were
assessed within 1 year of the diagnosis (patients with
incident disease), of whom 4 (14.8%) scored in the
mild range and 1 in the severe range on the ALS-
FTD-Q. The proportion of those with mild behav-
ioral disturbances of the patients with incident
disease was not significantly different from that of
patients with prevalent disease (2 test; not analyzed
for severe behavioral disturbances).
DISCUSSION This study shows the clinimetric
properties of a new screening instrument for behav-
ioral disturbances, which was constructed to avoid
bias due to motor and speech impairment in patients
with ALS. The ALS-FTD-Q showed substantial in-
ternal consistency and test-retest reliability and both
construct and clinical validity. Construct validity was
shown by high correlations of the ALS-FTD-Q with
frontal behavioral scales (same construct), intermedi-
ate correlations with frontal cognitive functions (re-
lated construct), and low correlations with anxiety/
depression and motor function (not related
constructs). The intermediate correlation between
fluency and the ALS-FTD-Q in our study is compa-
rable to findings by others and shows that the ques-
tionnaire measures a construct (frontal-mediated
behavior) that is related to fluency, supporting the
construct validity of the ALS-FTD-Q.26 In addition,
clinical validity was shown because the ALS-FTD-Q
discriminated between patients with a known differ-
ence in the presence of frontal behavioral distur-
bances. These good clinimetric properties and the
easy way of administering the ALS-FTD-Q make it a
feasible screening instrument in clinical practice as
well as for research projects.
The assessment of behavioral changes and espe-
cially bvFTD in patients with ALS is important in
clinical practice because bvFTD hinders adherence
to therapeutic interventions and may negatively in-
fluence survival. In addition, bvFTD has a great im-
pact on the relation of patients with ALS with their
caregivers.9–11
To our knowledge, 3 screening instruments for
nonmotor involvement (focusing on cognitive func-
tions) have been investigated in patients with
ALS.27–29 One screen contains 15 questions about
behavior27; 2 other screens included the FBI.28,29
Compared with these screening instruments, the
ALS-FTD-Q has 4 unique advantages. First, behav-
ioral items were selected from a systematic review of
case descriptions of 170 patients with ALS-bvFTD.18
Second, the phrasing of items was adjusted to take
motor and speech dysfunction into account. This
was done to minimize overestimation of behavioral
disturbances due to motor impairment. Third, the
ALS-FTD-Q has good clinimetric properties includ-
Table 2 Test scores and correlations of the ALS-FTD-Qwith other measures
of behavioral, cognitive, affective, andmotor functions in patients
with ALS
No.
Test score,
median (range)
Correlation with
ALS-FTD-Qa
ALS-FTD-Q 97 11 (056)
Frontal behavioral symptoms
FrSBe 95 56 (34129) 0.80
FBI 92 14 (039) 0.79
Frontal/executive functions
FAB 92 16 (318) 0.37b,c
Fluencyd 92 5.6 (1.924.3) 0.30
Cognitive functions
MMSE 97 26.8 (930) 0.32b,c
Affective functions
HADS 85 6 (024) 0.18
Motor functions
ALSFRS-R 97 33.0 (847) 0.18b
Abbreviations: ALS  amyotrophic lateral sclerosis; ALSFRS-R  ALS Functional Rating
ScaleRevised; ALS-FTD-Q  Amyotrophic Lateral Sclerosis-Frontotemporal Dementia-
Questionnaire; FAB  Frontal Assessment Battery; FBI  Frontal Behavioral Inventory;
FrSBe  Frontal Systems Behavior scale; HADS  Hospital Anxiety and Depression Scale;
MMSEMini-Mental State Examination.
a Correlation values are expressed as Spearman correlation coefficients.
b Negative as higher scores on the FAB,MMSE, andALSFRS-R indicate better performance.
c Extrapolated scores of the MMSE and FAB were used, corrected for missed items due to
motor impairment.
d Fluency represents the letter fluency index (correlation coefficient for category fluency
index 0.30).
1380 Neurology 79 September 25, 2012
ing internal consistency, construct validity, and clin-
ical validity. Fourth, test scores were compared with
both negative and positive control groups.
The point prevalence of severe and mild behav-
ioral disturbances according to the ALS-FTD-Q in
our patients with ALS without a prior diagnosis of
bvFTD is lower compared with the FBI (severe) and
the FrSBe (mild behavioral changes). Our data may
suggest that the FrSBe and FBI could overestimate
behavioral disturbances in patients with ALS (be-
cause of bias due to motor symptoms and dysar-
thria). The alternative explanation, i.e., a low
sensitivity of the ALS-FTD-Q, is less likely for 3 rea-
sons. First, we carefully selected items based on a
systematic review to capture the full range of neu-
robehavioral changes known to occur in ALS, includ-
ing delusions (paranoia), hallucinations, apathy, and
eating disturbances, which were recently found to be
prominent in patients with bvFTD with ALS.18,30,31
Second, our cutoff included all the patients with a
prior diagnosis of bvFTD and ALS-bvFTD, which
implies high sensitivity of the ALS-FTD-Q. Third,
the point prevalence of 7% severe behavioral distur-
bances in patients with ALS (without a prior diagno-
sis of bvFTD) in our cohort is in agreement with a
pooled prevalence of 8% bvFTD in 570 patients
with ALS in a systematic review of population-based
or outpatient clinicbased studies using family in-
terviews or clinical questionnaires.5,6,18
The proportion of patients with mild behavioral
changes as assessed with the ALS-FTD-Q (11%) is
lower than that in other studies (17%–50%).8,27,32,33
Earlier studies used instruments that have not been
validated for the assessment of behavioral changes in
ALS and contain items that have not been corrected
for motor impairment.8,11 In particular, apathy has
Figure 1 Correlations between the ALS-FTD-Q, the Frontal Behavioral
Inventory (FBI) (r 0.79; red), and the Frontal Systems Behavior
scale (FrSBe) (r 0.80; blue)
Figure 2 Boxplot with ALS-FTD-Q scores by diagnosis
ap  0.0001; bp  0.05, Mann-Whitney U Test. ALS  amyotrophic lateral sclerosis; ALS-FTD-Q  Amyotrophic Lateral
Sclerosis-Frontotemporal DementiaQuestionnaire; bvFTD behavioral variant of frontotemporal dementia.
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been shown to be present in up to 50% of patients
with ALS.11,26,34 However, apathy was studied with
the 14-item FrSBe apathy subscale, of which 7 items
are directly related to speaking and moving, which
may have led to overestimating motor-related mild
behavioral changes, e.g., apathy.11,26,34
The mild and severe behavioral changes in ALS in
the present study have to be interpreted in relation to
the cutoffs, which have to be further validated, and
in relation to the study population. We did not per-
form a receiver operating characteristic analysis to de-
fine the cutoffs of the ALS-FTD-Q because, for mild
behavioral disturbances, a gold standard in ALS does
not exist (the FrSBe could not be used for this pur-
pose as it contains motor- and speech-related items).
For severe behavioral disturbances, we could not use
the clinical diagnosis of bvFTD as a gold standard
because the bvFTD diagnoses were made before the
study (time between bvFTD diagnosis and assess-
ment ranged from 3 to 18 months).
Our study population was largely a prevalence co-
hort with a relatively long disease duration, and 18%
of patients had bulbar-onset ALS (compared with
30% in incidence cohorts).35 The design of this study
with more patients with prevalent than with incident
disease was chosen to examine our questionnaire in
patients with different disease durations, because pre-
vious studies described the development of bvFTD
in the course of ALS.36,37
In terms of further validation of the ALS-FTD-Q,
the high test-retest correlation should be replicated,
and the responsiveness (detection of changes over
time) of the ALSFTD-Q should be explored in depth
in a larger sample of patients with incident disease.
When sufficient data are collected, a factor analysis
may generate insight into subscales and a subset of
items that would suffice, which would make the scale
even more usable. Compared with a self-report instru-
ment, a potential drawback of the ALS-FTD-Q is that
it is limited to patients with a proxy. However, less than
2% of the patients we contacted did not participate be-
cause of the absence of a proxy. An important reason to
choose an observer-report scale in this study is that fron-
tal lobe dysfunction may interfere with the patient’s
ability to assess his or her own behavior. The ALS-
FTD-Q is a unique and novel instrument to be used in
the clinic for the screening of behavioral disturbances in
patients with ALS. It is a user-friendly tool with vali-
dated clinimetric characteristics.
AUTHOR CONTRIBUTIONS
Dr. Raaphorst: drafting/revising the manuscript for content, study con-
cept, analysis and interpretation of the data, acquisition of the data, statis-
tical analysis, and study coordination. E. Beeldman: drafting/revising the
manuscript for content, study concept, analysis and interpretation of the
data, acquisition of the data, and statistical analysis. Dr. Schmand: draft-
ing/revising the manuscript for content, analysis and interpretation of the
data, and study supervision. J. Berkhout: drafting/revising the manuscript
for content and acquisition of the data., Dr. Linssen, Dr. van den Berg,
Dr. Pijnenburg, Dr. Grupstra, J. Weikamp, Dr. Schelhaas, Dr. Papma,
Dr. van Swieten: drafting/revising the manuscript for content and
acquisition of the data. Dr. de Visser: drafting/revising the manuscript
for content, study concept, interpretation of the data, and study super-
vision. Dr. de Haan: drafting/revising the manuscript for content,
study concept, analysis and interpretation of the data, statistical analy-
sis, and study supervision.
ACKNOWLEDGMENT
The authors thank the referring physicians (in particular Dr. Esther Th.
Kruitwagen-van Reenen and Dr. H. van der Linde, rehabilitation physi-
cians), the Vereniging Spierziekten Nederland, Mary Gravemaker (for
recruiting patients), and Maria Bakker and Justine Aaronson (for translat-
ing the questionnaire).
DISCLOSURE
J. Raaphorst,. E. Beeldman, B. Schmand, J. Berkhout, and W. Linssen
report no disclosures. L. van den Berg received travel grants and consul-
tancy fees from Baxter; serves on scientific advisory boards for ARISLA
(the Italian ALS Association), Prinses Beatrix Fonds, Theirry Latran
Foundation, and Biogen Idec; serves as a consultant for and has received
funding for travel from Baxter International Inc.; serves on the editorial
board of Amyotrophic Lateral Sclerosis; and receives research support
from the Prinses Beatrix Fonds, Netherlands ALS Foundation, VSB
Fonds, Adessium Foundation, and the European Union. Y. Pijnenburg,
H. Grupstra, J. Weikamp, and H. Schelhaas report no disclosures. J.M.
Papma receives financial support by a grant from Alzheimer Nederland
(Dutch Alzheimer’s Society). J.C. van Swieten received research support
from AFTD (Association for Frontotemporal Dementias), Dioraphte
Foundation, Hersenstichting, and Nuts Ohra Foundation. M. de Visser
and R.J. de Haan report no disclosures. Go to Neurology.org for full
disclosures.
Received November 20, 2011. Accepted in final form May 8, 2012.
REFERENCES
1. Mackenzie IR, Rademakers R, Neumann M. TDP-43 and
FUS in amyotrophic lateral sclerosis and frontotemporal
dementia. Lancet Neurol 2010;9:995–1007.
2. Kew JJ, Goldstein LH, Leigh PN, et al. The relationship
between abnormalities of cognitive function and cerebral
activation in amyotrophic lateral sclerosis: a neuropsycho-
logical and positron emission tomography study. Brain
1993;116:1399–1423.
3. Hasegawa M, Arai T, Nonaka T, et al. Phosphorylated
TDP-43 in frontotemporal lobar degeneration and amyo-
trophic lateral sclerosis. Ann Neurol 2008;64:60–70.
4. Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH,
Olney RK, Miller B. Are amyotrophic lateral sclerosis pa-
tients cognitively normal? Neurology 2003;60:1094–
1097.
5. Ringholz GM, Appel SH, Bradshaw M, Cooke NA,
Mosnik DM, Schulz PE. Prevalence and patterns of cogni-
tive impairment in sporadic ALS. Neurology 2005;65:
586–590.
6. Phukan J, Elamin M, Bede P, et al. The syndrome of cog-
nitive impairment in amyotrophic lateral sclerosis: a
population-based study. J Neurol Neurosurg Psychiatry
2012:83:102108.
7. Raaphorst J, de Visser M, Linssen WH, de Haan RJ,
Schmand B. The cognitive profile of amyotrophic lateral
sclerosis: a meta-analysis. Amyotroph Lateral Scler 2010;
11:27–37.
1382 Neurology 79 September 25, 2012
8. Lillo P, Mioshi E, Zoing MC, Kiernan MC, Hodges JR.
How common are behavioural changes in amyotrophic lat-
eral sclerosis? Amyotroph Lateral Scler 2011;12:45–51.
9. Elamin M, Phukan J, Bede P, et al. Executive dysfunction
is a negative prognostic indicator in patients with ALS
without dementia. Neurology 2011;76:1263–1269.
10. Olney RK, Murphy J, Forshew D, et al. The effects of
executive and behavioral dysfunction on the course of
ALS. Neurology 2005;65:1774–1777.
11. Chio` A, Vignola A, Mastro E, et al. Neurobehavioral
symptoms in ALS are negatively related to caregivers’ bur-
den and quality of life. Eur J Neurol 2010;17:1298–1303.
12. Abrahams S, Leigh PN, Harvey A, Vythelingum GN,
Grise D, Goldstein LH. Verbal fluency and executive dys-
function in amyotrophic lateral sclerosis (ALS). Neuropsy-
chologia 2000;38:734–747.
13. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S,
Carusi DA, Gornbein J. The Neuropsychiatric Inventory:
comprehensive assessment of psychopathology in demen-
tia. Neurology 1994;44:2308–2314.
14. Grace J, Malloy P. Frontal Systems Behavior Scale
(FrSBe): Professional Manual. Lutz, FL: Psychological As-
sessment Resources; 2001.
15. Kertesz A, Davidson W, Fox H. Frontal behavioral inven-
tory: diagnostic criteria for frontal lobe dementia. Can
J Neurol Sci 1997;24:29–36.
16. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial
revisited: revised criteria for the diagnosis of amyotrophic
lateral sclerosis. Amyotroph Lateral Scler Other Motor
Neuron Disord 2000;1:293–299.
17. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal
lobar degeneration: a consensus on clinical diagnostic cri-
teria. Neurology 1998;51:1546–1554.
18. Raaphorst J, Beeldman E, De Visser M, De Haan RJ,
Schmand B. A systematic review of behavioural changes in
motor neuron disease. Amyotroph Lateral Scler Epub
2012 Mar 16.
19. Folstein MF, Folstein SE, McHugh PR. “Mini-mental
state”: a practical method for grading the cognitive state of
patients for the clinician. J Psychiatr Res 1975;12:189–
198.
20. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a
Frontal Assessment Battery at bedside. Neurology 2000;
55:1621–1626.
21. Schmand B, Groenink SC, van den Dungen M. Letter
fluency: psychometric properties and Dutch normative
data. Tijdschr Gerontol Geriatr 2008;39:64–76.
22. Zigmond AS, Snaith RP. The hospital anxiety and depres-
sion scale. Acta Psychiatr Scand 1983;67:361–370.
23. Cedarbaum JM, Stambler N. Performance of the Amyo-
trophic Lateral Sclerosis Functional Rating Scale (ALS-
FRS) in multicenter clinical trials. J Neurol Sci 1997;
152(suppl 1):S1S9.
24. Grossman AB, Woolley-Levine S, Bradley WG, Miller
RG. Detecting neurobehavioral changes in amyotrophic
lateral sclerosis. Amyotroph Lateral Scler 2007;8:56–61.
25. Gibbons ZC, Richardson A, Neary D, Snowden JS. Be-
haviour in amyotrophic lateral sclerosis. Amyotroph Lat-
eral Scler 2008;9:67–74.
26. Witgert M, Salamone AR, Strutt AM, et al. Frontal-lobe
mediated behavioral dysfunction in amyotrophic lateral
sclerosis. Eur J Neurol 2010;17:103–110.
27. Woolley SC, York MK, Moore DH, et al. Detecting fron-
totemporal dysfunction in ALS: utility of the ALS Cogni-
tive Behavioral Screen (ALS-CBS). Amyotroph Lateral
Scler 2010;11:303–311.
28. Flaherty-Craig C, Brothers A, Dearman B, Eslinger P,
Simmons Z. Penn State screen exam for the detection of
frontal and temporal dysfunction syndromes: application
to ALS. Amyotroph Lateral Scler 2009;10:107–112.
29. Gordon PH, Wang Y, Doorish C, et al. A screening assess-
ment of cognitive impairment in patients with ALS. Amy-
otroph Lateral Scler 2007;8:362–365.
30. Lillo P, Garcin B, Hornberger M, Bak TH, Hodges JR. Neu-
robehavioral features in frontotemporal dementia with amyo-
trophic lateral sclerosis. Arch Neurol 2010;67:826–830.
31. Coon EA, Sorenson EJ, Whitwell JL, Knopman DS, Jo-
sephs KA. Predicting survival in frontotemporal dementia
with motor neuron disease. Neurology 2011;76:1886–
1893.
32. Murphy JM, Henry RG, Langmore S, Kramer JH, Miller
BL, Lomen-Hoerth C. Continuum of frontal lobe impair-
ment in amyotrophic lateral sclerosis. Arch Neurol 2007;
64:530–534.
33. Meier SL, Charleston AJ, Tippett LJ. Cognitive and be-
havioural deficits associated with the orbitomedial prefron-
tal cortex in amyotrophic lateral sclerosis. Brain 2010;133:
3444–3457.
34. Woolley SC, Zhang Y, Schuff N,WeinerMW,Katz JS. Neu-
roanatomical correlates of apathy in ALS using 4 Tesla diffu-
sion tensor MRI. Amyotroph Lateral Scler 2011;12:52–58.
35. Huisman MH, de Jong SW, van Doormaal PT, et al. Pop-
ulation based epidemiology of amyotrophic lateral sclerosis
using capture-recapture methodology. J Neurol Neurosurg
Psychiatry 2011;82:11651170.
36. Gentileschi V, Muggia S, Poloni M, Spinnler H. Fronto-
temporal dementia and motor neuron disease: a neuropsy-
chological study. Acta Neurol Scand 1999;100:341–349.
37. Vance C, Al-Chalabi A, Ruddy D, et al. Familial amyotro-
phic lateral sclerosis with frontotemporal dementia is
linked to a locus on chromosome 9p13.2-21.3. Brain
2006;129:868–876.
Neurology 79 September 25, 2012 1383
